Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
obinutuzumab + polatuzumab vedotin + venetoclax
- Development stage
- Unknown
- Lead developer
- Roche
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
A combination therapy of **obinutuzumab (a humanized anti-CD20 monoclonal antibody)**, **polatuzumab vedotin (an antibody-drug conjugate targeting CD79b with a monomethyl auristatin E payload)**, and **venetoclax (a selective inhibitor of BCL-2)**. This regimen has been studied in patients with relapsed or refractory follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). The combination works synergistically: obinutuzumab targets CD20 to induce B-cell lysis; polatuzumab vedotin delivers cytotoxic MMAE to CD79b-positive B cells, causing cell cycle arrest and apoptosis; venetoclax inhibits BCL-2 to promote apoptosis. Together, these mechanisms aim to overcome resistance and improve remission rates in aggressive B-cell lymphomas[1][3][4][5][8].
02
Targets
MicrotubuleBCL-2 (BCL-2 family)CD20 (B-lymphocyte antigen CD20)B-cell antigen receptor complex-associated protein beta chain
Beyond the preview
Go deeper on obinutuzumab + polatuzumab vedotin + venetoclax.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on obinutuzumab + polatuzumab vedotin + venetoclax.